Vaccine to prevent HPV-related cancers
Part of Cancer, Infections clinical trials.
This trial tests a new vaccine (RG1-VLP) designed to prevent HPV-related cancers. It is for healthy women who have not been vaccinated against HPV before and are willing to receive three doses of the vaccine over several months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a woman between 18 and 60 years old
- Have no history of HPV vaccination (like Gardasil or Cervarix)
- Be generally healthy (no major medical conditions)
- Have normal blood counts and organ function
- Not be pregnant or breastfeeding, and agree to use contraception (if able to become pregnant)
- Have no prior or current genital warts or abnormal cell changes in the cervix, anus, vagina, or vulva
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new vaccine (pBI-11) given with a device that uses mild electric pulses to help the vaccine enter cells. It is for people who have HPV16 or 18 but no high-grade cervical changes.
This early-phase study tests a vaccine designed to help your immune system fight HPV16, a type of human papillomavirus linked to abnormal cells in the cervix. You may or may not be living with HIV, and the team will check safety and immune response after giving the vaccine in a specific way.
This trial tests two experimental vaccines to boost the immune system against HPV 16. Healthy relatives of patients with HPV 16 cancer receive the vaccines, then donate blood cells for research.
This study tests a new injection (RG002) for women with a cervical precancer called CIN 2 or CIN 3 that is caused by HPV types 16 or 18. The goal is to see if the treatment can help the body clear the precancer without needing surgery.
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
This study tests how HPV antibodies work in urine samples from women with HPV16 before and after they get the HPV vaccine (Gardasil 9). It helps researchers understand how the vaccine protects against HPV.
Hear when a new Human Papillomavirus-Related Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.